drug
adalimumab
Marketedupdated 3mo agoby $ABBV AbbVie Inc.
Approvedannual revenue · 2024–2024peak $9.0B
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval432 co-mentions · 155 sources
- drugHUMIRA359 co-mentions · 156 sources
- drugAMJEVITA168 co-mentions · 94 sources
- drugABRILADA156 co-mentions · 88 sources
- drugYUSIMRY152 co-mentions · 86 sources
- company$ABBVAbbVie Inc.122 co-mentions · 61 sources
- drugYUFLYMA28 co-mentions · 14 sources
- drugHADLIMA26 co-mentions · 13 sources
Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.
indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
all catalysts(61)
approval · 61
Dec 31, 2002
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 12, 2003
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 18, 2004
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 30, 2004
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 3, 2005
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 3, 2005
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 23, 2006
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 28, 2006
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 9, 2006
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 9, 2006
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 16, 2007
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 27, 2007
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 30, 2007
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 5, 2007
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jan 18, 2008
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 21, 2008
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 11, 2009
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 8, 2010
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 29, 2010
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 29, 2010
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 18, 2010
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 25, 2011
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 14, 2011
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 13, 2011
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 7, 2011
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 13, 2011
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 26, 2011
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 24, 2012
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 28, 2012
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 24, 2013
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 13, 2013
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 19, 2013
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 26, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 14, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
May 30, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Aug 7, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 23, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 30, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 29, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 6, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 24, 2014
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 9, 2015
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 23, 2015
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jun 30, 2016
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 17, 2016
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 27, 2017
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 21, 2017
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Apr 28, 2017
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 14, 2017
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Aug 2, 2018
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Sep 28, 2018
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Oct 16, 2018
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 6, 2018
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jan 11, 2019
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Mar 11, 2020
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 16, 2020
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 16, 2020
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Feb 24, 2021
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Nov 3, 2023
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Jul 16, 2025
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Dec 23, 2025
approval
$ABBV250.09+0.85%
HUMIRA (ADALIMUMAB) — FDA approval
adalimumab
→
Trials studying adalimumab
- phase3A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- phase1A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
- phase4A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
- phase4A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- phase3A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
- phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- phase4A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
- phase3A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
News(5)
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trialMoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.fiercebiotech · 2d ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 11d ago
- cAMPfield lands $180M to build gut disease drugThe biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.biopharma_dive · 1mo ago
- Biogen adds more immune drugs in $1B buyout of secretive startup RayTheraThe companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.biopharma_dive · 1mo ago
- Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.stat · 3mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that